Development of clinical nano-particles and oral gene medicine

Abstract

Abstract: Oral medicine is one of the main methods for disease prevention and treatment.It is very popular in healthcare due to its convenience, efficiency, comfort and safety.However, there is still a lack of qualitative and quantitative information how about macro-molecules, and nano-particles in particular, are taken up and absorbed in the gastrointestinal tract.This paper systematically describes relationships between features of nano-particles, protein transduction, and uptake cell types at gastrointestinal sites and the uptake and absorbance of nano-particles.Development of the route for orally-delivered gene medicine, and particularly the uptake, distribution, pharmakinetics, feasibility and system evaluation of orally viral vectors is explored.Trends in and obstacles to the delivery, expression, production and release of oral gene medicine are also discussed.

Key words: clinical, nano-particles, oral, gene, medicine, therapy

CLC Number:

R966

XU Rui-an. Development of clinical nano-particles and oral gene medicine[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2007, 12(3): 241-249.

References

1 许瑞安, 肖卫东, 主编.分子基因药物学[M].北京大学&北京大学医学出版社联合出版, 2007:1-28.
2 Page DT, Cudmore S.Innovations in oral gene delivery:challenges and potentials[J].Drug Discov Today, 2001;6:92-101.
3 Delie F.Evaluation of nano-and microparticle uptake by the gastrointestinal tract[J].Adv Drug Deliv Rev, 1998;34:221-233.
4 Pappo J, Ermak TH.Uptake and translocation of fluorescent latex particles by rabbit Peyer' s patch follicle epithelium:a quantitative model for M cell uptake[J].Clin Exp Immunol, 1989; 76:144-148.
5 Florence AT, Hillery AM, Hussain N, et al.Factors affecting the oral uptake and translocation of polystyrene nanoparticles: histological and analytical evidence[J].J Drug Target, 1995;3: 65-70.
6 Frey A, Giannasca KT, Weltzin R, et al.Role of the glycocalyx in regulating access of microparticles to apical plasma membranes of intestinal epithelial cells:implications for microbial attachment and oral vaccine targeting[J].J Exp Med, 1996;184: 1045-1059.
7 Desai MP, Labhasetwar V, Amidon GL, et al.Gastrointestinal uptake of biodegradable microparticles:effect of particle size [J].Pharm Res, 1996;13:1838-1845.
8 Bonduelle S, Carrier M, Pimienta C, et al.Tissue concentration of nanoencaps ulated radiolabeled cyclosporin following peroral delivery in mice or ophthalmic application in rabbits[J]. Eur J Phar Biopharm, 1996;42:313-319.
9 Nefzger M, Kreuter J, Voges R, et al.Distribution and elimination of polymethyl methacrylate nanoparticles after peroral administration to rats[J].J Pharm Sci, 1984;73:1309-1311.
10 Wells Cl, MaddausMA, Erlandsen SL, et al.Evidence for the phagocytic transport of intestinal particles in dogs and rats[J]. Infect Immun, 1988;56:278-282.
11 Smith MW, James PS, Tivey DR.M cell numbers increase after transfer of SPF mice to a normal animal house environment [J].Am J Pathol, 1987;128:385-389.
12 JepsonMA, ClarkMA, Foster N, et al.Targeting to intestinal M cells[J].J Anat, 1996;189:507-516.
13 Brayden DJ, Baird AW.Apical membrane receptors on intestinal M cells:potential targets for vaccine delivery[J].Adv Drug Deliv Rev, 2004;56:721-726.
14 Pinto-Alphandary H, Aboubakar M, Jaillard D, et al.Visualization of insulin-loaded nanocapsules: in vitro and in vivo studies after oral administration to rats[J].Pharm Res, 2003; 20:1071-1084.
15 Rescigno M, Urbano M, Valzasina B, et al.Dendritic cells express tight junction proteins and penetrate gut epithelial monolayers to sample bacteria[J].Nat immunol, 2001;2:361-367.
16 Green M, Loewenstein PM.Autonomous functional domains of chemically synthesized human immunodeficiency virus tat transactivator protein[J].Cell, 1988;55:1179-1188.
17 Frank AD, Pabo CO.Cellular uptake of the tat protein from human immunodeficiency virus[J].Cell, 1988;55:1189-1193.
18 熊符, 张成, 于美娟.蛋白转导在基因治疗中的应用[J].国际生物学工程杂志, 2006;29:250-254.
19 Efrat S, Surana M, Fleischer N.Glucose induces insulin gene transcription in a murine pancreatic beta-cell line[J].J Biol Chem, 1991;266:11141-11143.
20 Del G, Moore V, Payne RM.Transactivator of transcription fusion protein transduction causes membrane inversion[J].J Biol Chem, 2004;179:32541-32543.
21 Eguchi A, Akurta T, Okuyama H.et al.Protein transduction domain of HIV-1 Tat protein promotes efficient delivery of DNA into mammalian cells[J].J Biol Chem, 2001;276:26204-26210.
22 Lambkin I, Pinilla C.Targeting approaches to oral drug delivery[J].Expert Opin Biol Ther, 2002;2:67-73.
23 Thanos CG, Liu Z, Reineke J, et al.Improving relative bioavailability of dicumarol by reducing particle size and adding the adhesive poly(fumaric-co-sebacic) anhydride[J].Pharm Res, 2003;20:1093-1100.
24 Vajdy M, O' Hagan DT.Microparticles for intranasal immunization[J].Adv Drug Delib Rev, 2001;51:127-141.
25 Eldridge JH, Meulbroek JA, Staas JK, et al.Vaccine-containing biodegradable microspheres specifically enter the gut-associated lymphoid tissue following oral administration and induce a disseminated mucosal immune response[J].Adv ExpMed Biol, 1989;251:191-202.
26 Giannasca PJ, Giannasca KT, Leichtner AM, et al.Human intestinalM cells display the sialyl Lewis A antigen[J].Infect Immu, 1999;67:946-953.
27 Wu Y, Wang X, Csencsits KL, et al.M cell-targeted DNA vaccination[J].Proc Natl Acad Sci US A, 2001;98:9318-9323.
28 Tyler KL, Clarke P, DeBiasi RL, et al.Reoviruses and the host cell[J].Trends Microbiol, 2001;9:560-564.
29 Heppner FL, Christ AD, Klein MA, et al.Transepithelial prion transport by M cells[J].Nat Med, 2001;7:976-977.
30 Heggebo R, Gonzalez L, Press CM, et al.Disease-associated PrP in the enteric nervous system of scrapie-affected Suffolk sheep[J].J Gen Virol, 2003;84:1327-1338.
31 Terry LA, Marsh S, Ryder SJ, et al.Detection of disease-specific PrP in the distal ileum of cattle exposed orally to the agent of bovine spongiform encephalopathy[J].Vet Rec, 2003;152: 387-392.
32 Huang FP, Farquhar CF, Mabbott NA, et al.Migrating intestinal dendritic cells transport PrP(Sc) from the gut[J].J Gen Virol, 2002;83:267-271.
33 Ghosh S.Intestinal entry of prions[J].Z Gastroenterol, 2002; 40:37-39.
34 Shmakov AN, Bode J, Kilshaw PJ, et al.Diverse patterns of expression of the 67-kD laminin receptor in human small intestinal mucosa:potential binding sites for prion proteins[J] ? J Pathol, 2000;191:318-322.
35 El-Bahi S, Caliot E, BensM, et al.Lymphoepithelial interactions trigger specific regulation of gene expression in the M cellcontaining follicle-associated epithelium of Peyer' s patches[J]. J Immunol, 2002;168:3713-3720.
36 Kerneis S, Bogdanova A, Kraehenbuhl JP, et al.Conversion by Peyer' s patch lymphocytes of human enterocytes into M cells that transport bacteria[J].Science, 1997;277:949-952.
37 Fotopoulos G, Harari A, Micheetti P, et al.Transepithelial transport of HIV-1 by M cells is receptor-mediated[J].Proc Natl Acad Sci USA, 2002;99:9410-9414.
38 Ouzilou L, Caliot E, Pelletier I, et al.Poliovirus transcytosis through M-like cells[J].J Gen Virol, 2002;83:2177-2182.
39 Iwasaki A, Welker R, Mueller S, et al.Immunofluorescence analysis of poliovirus receptor expression in Peyer' s patches of humans, primates, and CD155 transgenic mice:implications for poliovirus infection[J].J Infect Dis, 2002;186:585-592.
40 Lelouard H, Reggio H, Roy C, et al.Glycocalyx on rabbit intestinalM cells displays carbohydrate epitopes from Muc2[J]. Infect Immun, 2001;69:1061-1071.
41 Xu RA, Ma H, Li H, et al.Trends in Gene Ther Res[M]. New York:NOVA Science Publisher, 2006.
42 Takamura S, Niikura M, Li TC, et al.DNA vaccine-encapsulated virus-like particles derived from an orally transmissible virus stimulate mucosal and sy stemic immune responses by oral administration[J].Gene Ther, 2004;11:628-635.
43 Xu RA, Janson CG, Mastakov M, et al.Quantitative compareson of expression with adeno-associated virus (AAV-2) brainspecific gene cassettes[J].Gene Ther, 2001;8:1323-1332.
44 During MJ, Xu RA, Young D, et al.Peroral gene therapy of lactose intolerance using an adeno-associated virusvector[J]. NatMed, 1998;4:1131-1136.
45 Xu RA, Herrison P, Chen M, et al.Cytoglobin protects against damage-induced liver fibrosis[J].Mol Ther, 2006;13: 1093-1100.
46 During MJ, Symes CW, Lawlor PA, et al.An oral vaccine against NMDAR1 with efficacy in experimental stroke and epilepsy[J].Science, 2000;287:1453-1560.
47 Xu RA.Oral gene delivery for cancer therapy[J].Cancer Gene Ther, 2004;11:843.
48 Shenk T.Adenoviridae:the viruses and their application[M]. Fundamental Virology.Third edition.Philadelphia:Lippincott-Raven Publishers, 1996:888-994
49 Ogawara K, Rots MG, Kok RJ, et al.A novel strategy to modify adenovirus tropism and enhance transgene delivery to activated vascular endothelial cells in vitro and in vivo[J].Human Gene Therapy, 2004;15:433-443.
50 MinekusM, Marteau P, Havenaar R, et al.A multi-compartmental dynamic computer-controlled model simulating the stomach and small intestine[J].ATLA, 1995;23:197-209.
51 Steidler L, HansW, Schotte L, et al.Treatment of murine colitis by Lactococcus lactis secreting interleukin-10[J].Science, 2000;289:1352-1355.

[1]	WANG Ruyue, XIE Fei, WANG Xin, LI Hongyu. Therapeutic effect of lienal polypeptide injection on bone marrow suppression and immunodeficiency in KM mice following chemotherapy [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(9): 1000-1007.
[2]	XU Yiqi, WU Qian, LIU Shu, LIU Fan, XING Chunyan, LI Qin, HE Junjun, HE Chunling, ZHAO Yongli, GAO Jialin. Clinical efficacy and anti-inflammation/anti-fibrosis effect of tripterygium glycosides in the treatment of diabetic nephropathy [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(9): 1034-1042.
[3]	HE Lihua, ZHU Xiuzhi, JIANG Yizhou. Research progress on immunotherapy for triple-negative breast cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(8): 842-853.
[4]	ZHANG Huyunlong, ZHU Xiuzhi, JIN Xi, SHAO Zhimin. Mechanisms of endocrine-resistance and therapeutic breakthroughs in hormone receptor-positive, HER2-negative breast cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(8): 854-865.
[5]	LUO Shiping, ZHANG Jie, YU Yushuai, SONG Chuangui. Advances in targeted therapy for HER2-positive breast cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(8): 876-886.
[6]	XIANG Yimei, ZHANG Ningning, HUANG Yuxin, ZENG Xiaohua. Research progress of biomarkers related to the efficacy of HER2 positive breast cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(8): 887-897.
[7]	WANG Chaoyi, SONG Qiang, XIONG Xin, WANG Mengyuan. Research progress on diagnosis and treatment of granulomatous lobular mastitis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(8): 910-917.
[8]	ZHONG Wei, SHI Shuxia, QIN Qinyue, YU Guo. Measurement tools and rationality evaluation of clinical research coordinator's work ability and workload [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(8): 937-947.
[9]	ZHANG Taotao, SU Wenxiu, TIAN Limin. Research progress on the relationship between subclinical hypothyroidism and depression [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(8): 954-960.
[10]	LIU Min, KONG Xiang, ZHANG Ye, GU Yifei, XIANG Xuemei, HE Qing, HUANG Kai. Analysis of reasons for screening failure of healthy subjects in clinical trials of orally inhaled drug products [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(7): 758-766.
[11]	HOU Qiong, LIU Fei, CHEN Chuanrong. Immunotherapy combined with anti-angiogenic drugs and chemotherapy in negative driver gene and advanced non-small cell lung cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(7): 775-779.
[12]	WANG Anjing, WANG Yaya, LIANG Xuan, YAN Yajie, SU Jing, LI Caidong. Research progress on mechanisms and therapeutic drugs of peroxisome proliferator-activated receptor in treatment of cholestatic liver disease [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(7): 796-808.
[13]	YU Qiaoling, ZHAI Weiwei, LIU Ping, QIU Bo, WU Huizhen. Research progress in plasma concentration monitoring of rivaroxaban [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(7): 809-817.
[14]	FU Ting, LI Fang, PAN Dayan, XIA Yuanyuan, ZHANG Qiuyuan. miR-718 from exosomes of lung cancer cells induces angiogenesis by targeting PTEN [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(6): 624-632.
[15]	LI Qinghua, ZHAO Yan, ZHAO Haigang, GAO Pengfei, XU Bingxin. Value of ABCB1 G2677T gene polymorphism detection in lipid-lowering therapy with atorvastatin in patients suffered from ischemic stroke [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(6): 633-640.